secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001654954-23-013555
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI reports Multikine cuts death risk by half in target head & neck cancer patients; seeks accelerated approval
--------------------------------------------------------------------------------

- CEO Geert Kersten's employment extended to August 31, 2027.
- Multikine shows 28.6% absolute 5-year overall survival benefit vs control (p=0.0015) in target population.
- Hazard ratio 0.349; risk of death cut in half at 5 years in target patients.
- >35% pre-surgery tumor reductions/downstages (p<0.01) with low PD-L1 expression.
- Company plans conditional/accelerated approval worldwide without waiting for new trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495423013555/0001654954-23-013555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-013555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer